scholarly journals Circulating Exosomal miRNAs as Biomarkers for the Diagnosis and Prognosis of Colorectal Cancer

2020 ◽  
Vol 22 (1) ◽  
pp. 346
Author(s):  
Katiusse Alves dos Santos ◽  
Isabelle Cristina Clemente dos Santos ◽  
Carollyne Santos Silva ◽  
Hériks Gomes Ribeiro ◽  
Igor de Farias Domingos ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Genetic Factors ◽  
Malignant Tumors ◽  
Noncoding Rnas ◽  
Distant Metastases ◽  
Stable Form ◽  
Overall Survival Rate ◽  
Small Noncoding Rnas ◽  
Diagnosis And Prognosis ◽  
Exosomal Mirnas

Colorectal cancer (CRC) is one of the most common malignant tumors in the gastrointestinal tract. It is a multifactorial disease that involves environmental factors, genetic factors, and lifestyle factors. Due to the absence of specific and sensitive biomarkers, CRC patients are usually diagnosed at an advanced stage and consequently suffer from a low 5-year overall survival rate. Despite improvements in surgical resection and adjuvant chemotherapy, the prognosis of patients with CRC remains unfavorable due to local and distant metastases. Several studies have shown that small noncoding RNAs, such as microRNAs packed in exosomes, are potential biomarkers in various types of cancers, including CRC, and that they can be detected in a stable form in both serum and plasma. In this review, we report the potential of circulating exosomal miRNAs to act as biomarkers for the diagnosis and prognosis of CRC.

scholarly journals Chemokines—What Is Their Role in Colorectal Cancer?

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482090338 ◽  
Author(s):  
Sara Pączek ◽  
Marta Łukaszewicz-Zając ◽  
Barbara Mroczko
Keyword(s):  
Colorectal Cancer ◽  
Current Knowledge ◽  
Early Stage ◽  
Distant Metastases ◽  
Cell Types ◽  
Diagnosis And Prognosis ◽  
Novel Biomarkers ◽  
Specific Receptors ◽  
Common Malignancy

Colorectal cancer (CRC) is one of the leading causes of cancer-related death. It is the second most frequently diagnosed malignancy in Europe and third worldwide. Colorectal malignancies diagnosed at an early stage offer a promising survival rate. However, advanced tumors often present distant metastases even after the complete resection of a primary tumor. Therefore, novel biomarkers of CRC are sorely needed in the diagnosis and prognosis of this common malignancy. A family of chemokines are composed of small, secreted proteins. They are best known for their ability to stimulate the migration of several cell types. Some investigations have indicated that chemokines are involved in cancer development, including CRC. This article presents current knowledge regarding chemokines and their specific receptors in CRC progression. Moreover, the prime aim of this review is to summarize the potential role of these proteins as biomarkers in the diagnosis and prognosis of CRC.

scholarly journals Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-13 ◽  
Author(s):  
Jia-jun Wang ◽  
Xin Wang ◽  
Yong-xi Song ◽  
Jun-hua Zhao ◽  
Jing-xu Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
General Population ◽  
Malignant Tumors ◽  
Noncoding Rnas ◽  
Screening Methods ◽  
Potential Applications ◽  
Novel Biomarkers ◽  
Noninvasive Biomarkers ◽  
Regulatory Functions ◽  
Resistance To Chemotherapy

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, causing a large number of cancer-related deaths each year. Patients are usually diagnosed at advanced and incurable stages due to the lack of suitable screening methods for early detection. Noncoding RNAs (ncRNAs), including small and long noncoding RNAs (lncRNA), are known to have significant regulatory functions, and accumulating evidence suggests that circulating ncRNAs have potential applications as noninvasive biomarkers for diagnosing CRC, evaluating its prognosis, or predicting chemosensitivity in the general population. In this review, we summarize the origins of circulating ncRNAs and provide details of single and multiple circulating ncRNAs that might have roles as diagnostic and prognostic biomarkers in CRC. We end by discussing circulating ncRNAs that may distinguish patients with resistance to chemotherapy.

The role of preoperative chemotherapy for colorectal cancer metastases in the liver with the lack of RAS mutations

2016 ◽  
Vol 21 (5) ◽  
pp. 238-243
Author(s):  
A. F Lazarev ◽  
K. G Mamontov ◽  
A. G Kotelnikov ◽  
Sergey L. Khays ◽  
V. A Lubennikov
Keyword(s):  
Colorectal Cancer ◽  
Malignant Tumors ◽  
Distant Metastases ◽  
Morbidity Rate ◽  
Cancer Metastases ◽  
Modern Drug ◽  
Medicinal Treatment ◽  
Common Causes ◽  
The World ◽  
The One

Colorectal cancer (CRC) is one of the most common malignancies, occupying the third place in the world among malignant tumors morbidity rate and the 4th place on the causes of death. Every year in the world there are diagnosed more than 1.3 millions of new cases of the disease. The mortality rate continues to be one of the most common causes in the structure of cancer incidence. In Russia, each year there are diagnosed more than 60 thousands of new cases of colorectal cancer. For the last time the incidence increased by 11%, out of them more than 17 thousands patients show newly diagnosed distant metastases. In the absolute majority of cases metastases in the liver are firstly detected in 2-3 years. Liver is the organ- the most commonly affected by metastases. Methods of medicinal treatment of CRC metastases are of great importance and allowed to greatly improve the life expectancy of patients. Median overall survival (OS) is 35-40 months. The one of the last achievement of the modern drug therapy of metastatic CRC was the appearance of the preparation Cetuximab. Blocking of the KRAS gene is a key compartment of the signaling pathways that transmit extracellular growth signals from the surface of the cell to the nucleus. Further signals are transmitted via the cascade into the cellular nucleus, regulating cell growth, proliferation, angiogenesis, invasion and metastasis. Results of the research of PRIME, PEAK and FIRE-3 confirm the advantage of supplement ofpanitumumab or cetuximab to chemotherapy regimens FOLFOX or FOLFIRI in patients with wild-type Ras.

Noncoding RNAs and Colorectal Cancer:A General Overview

MicroRNA ◽  
2020 ◽  
Vol 09 ◽  
Author(s):  
Jonathan Souza Sarraf ◽  
Taynah Cascaes Puty ◽  
Emanuely Magno da Silva ◽  
Thais Suellen Ramos Allen ◽  
Yasmim Souza Sarraf ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Noncoding Rnas ◽  
Target Prediction ◽  
Small Interfering Rnas ◽  
Noncoding Regions ◽  
Rna Molecules ◽  
Small Noncoding Rnas ◽  
Non Coding Rnas ◽  
Nucleolar Rnas

Background: Colorectal cancer (CRC) is the second most prevalent cancer in the world when nonmelanoma skin cases are not considered. Different epigenetic mechanisms play a role in the development of cancer. Noncoding RNAs (ncRNAs) are RNA molecules transcribed from noncoding regions of the genome. These are divided into sncRNAs (small noncoding RNAs: <200 nucleotides - including miRNAs [microRNAs], siRNAs [small interfering RNAs], piRNAs [piwi-interacting RNAs], snoRNAs [small nucleolar RNAs]) and lncRNAs (long noncoding RNAs: >200 nucleotides – includingcircular RNAs [circRNAs]). NcRNAs can act as oncogenes or as tumor suppressor genes in CRC and are potential biomarkers of diagnosis, with possible clinical implications. Objective: This article aims to make a general review around all types of non-coding RNAs and influence in colorectal cancer, focus in biomarkesof CRC and their possible applications in clinical practice, as well as review their biogenesis and functions. Furthermore, we seek to summarize possible databases available for new searches and studies that require sequence annotation, comparison sequences and target prediction for ncRNAs with the hope ofgathering information that can aid in the process of understanding and translating the use of ncRNAs into clinical practice.

scholarly journals Epigenetic Biomarkers: Potential Applications in Gastrointestinal Cancers

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Jiaqiu Li ◽  
Hongchuan Jin ◽  
Xian Wang
Keyword(s):  
Colorectal Cancer ◽  
Chromatin Remodeling ◽  
Noncoding Rnas ◽  
Clinical Applications ◽  
Epigenetic Mechanisms ◽  
Gastrointestinal Cancers ◽  
Diagnosis And Prognosis ◽  
Epigenetic Biomarkers ◽  
Cancer Initiation ◽  
Potential Applications

Genetics and epigenetics coregulate the cancer initiation and progression. Epigenetic mechanisms include DNA methylation, histone modification, chromatin remodeling, and noncoding RNAs. Aberrant epigenetic modifications play a fundamental role in the formation of gastrointestinal cancers. Advances in epigenetics offer a better understanding of the carcinogenesis and provide new insights into the discovery of biomarkers for diagnosis, and prognosis prediction of human cancers. This review aims to overview the epigenetic aberrance and the clinical applications as biomarkers in gastrointestinal cancers mainly gastric cancer and colorectal cancer.

Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer

2017 ◽  
Vol 181 ◽  
pp. 108-120 ◽  
Author(s):  
Mingjiao Weng ◽  
Di Wu ◽  
Chao Yang ◽  
Haisheng Peng ◽  
Guangyu Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Noncoding Rnas ◽  
Diagnosis And Prognosis

Identification of long noncoding RNAs as potential novel diagnosis and prognosis biomarkers in colorectal cancer

2016 ◽  
Vol 142 (11) ◽  
pp. 2291-2301 ◽  
Author(s):  
Rui Wang ◽  
Lutao Du ◽  
Xiaoyun Yang ◽  
Xiumei Jiang ◽  
Weili Duan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Diagnosis And Prognosis

scholarly journals Exosomal miRNAs in Heart Disease

Physiology ◽  
2016 ◽  
Vol 31 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Claudio Iaconetti ◽  
Sabato Sorrentino ◽  
Salvatore De Rosa ◽  
Ciro Indolfi
Keyword(s):  
Heart Disease ◽  
Posttranscriptional Regulation ◽  
Functional Role ◽  
Regulation Of Gene Expression ◽  
Noncoding Rnas ◽  
Small Noncoding Rnas ◽  
Micro Rnas ◽  
Exosomal Mirnas ◽  
New Biomarkers ◽  
Potential Use

Micro-RNAs (miRNAs) are small noncoding RNAs involved in the posttranscriptional regulation of gene expression. Exosomes have recently emerged as novel elements of intercellular communication in the cardiovascular system. Exosomal miRNAs could be key players in intercellular cross-talk, particularly during different diseases such as myocardial infarction (MI) and heart failure (HF). This review addresses the functional role played by exosomal miRNAs in heart disease and their potential use as new biomarkers.

scholarly journals DANSR: A Tool for the Detection of Annotated and Novel Small RNAs

2022 ◽  
Vol 8 (1) ◽  
pp. 9
Author(s):  
Jin Zhang ◽  
Abdallah M. Eteleeb ◽  
Emily B. Rozycki ◽  
Matthew J. Inkman ◽  
Amy Ly ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Small Rna ◽  
Small Rnas ◽  
Noncoding Rna ◽  
Noncoding Rnas ◽  
Biologically Relevant ◽  
Small Noncoding Rna ◽  
Small Noncoding Rnas ◽  
Rna Analysis ◽  
Length Range

Existing small noncoding RNA analysis tools are optimized for processing short sequencing reads (17–35 nucleotides) to monitor microRNA expression. However, these strategies under-represent many biologically relevant classes of small noncoding RNAs in the 36–200 nucleotides length range (tRNAs, snoRNAs, etc.). To address this, we developed DANSR, a tool for the detection of annotated and novel small RNAs using sequencing reads with variable lengths (ranging from 17–200 nt). While DANSR is broadly applicable to any small RNA dataset, we applied it to a cohort of matched normal, primary, and distant metastatic colorectal cancer specimens to demonstrate its ability to quantify annotated small RNAs, discover novel genes, and calculate differential expression. DANSR is available as an open source tool.

Sign in / Sign up

Export Citation Format

Share Document